Surgical approaches and outcomes in the treatment of gastric cancer

Seminars in Radiation Oncology

Volumn 12, Issue 2, 2002, Pages 162-169

  Kim, Hong Jin ^a,b   Karpeh, Martin S ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMPETENCE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GASTRECTOMY; HUMAN; LYMPH NODE DISSECTION; MORBIDITY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; STOMACH CARCINOMA; SURGEON; SURGICAL APPROACH; SURGICAL MORTALITY; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0036094373     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1053/srao.2002.30818     Document Type: Article

References (53)

1. Surgery: Independent prognostic factor in curable and far advanced gastric cancer
2. Influence of surgery on outcomes in gastric cancer
3. Rationale for extended lymphadenectomy in gastrectomy for carcinoma
4. Surgical results in gastric cancer
5. Results of surgery on 6,589 gastric cancer patients and immunochemosurgery as the best treatment of advanced gastric cancer
6. Extended lymph-node dissection for gastric cancer: Dutch Gastric Cancer Group
7. Patient survival after D1 and D2 resections for gastric cancer: Long-term results of the MRC randomized surgical trial: Surgical Co-operative Group
8. Extended lymphadenectomy is associated with a survival benefit for nodenegative gastric cancer
9. Relevant prognostic factors in gastric cancer: Ten-year results of the German Gastric Cancer Study
10. Lymph node staging in gastric cancer: Is location more important than number? Ananalysis of 1,038 patients
11. Analysis of 154 actual five-year survivors of gastric cancer
12. The roles of chemotherapy and surgery in gastric carcinoma and the influence of prognostic factors on survival
13. Postoperative outcome and sites of recurrence in patients following curative resection of gastric cancer
14. The role of radiation therapy in gastric cancer
15. Recurrence following curative resection for gastric carcinoma
16. Adenocarcinoma of the stomach: Autopsy observations with therapeutic implications for the radiation oncologist
17. Adenocarcinoma of the stomach: Areas of failure in a reoperation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy
18. Adjuvant chemotherapy in operable gastric cancer: 5 year follow-up of first British Stomach Cancer Group trial
19. Long-term follow-up of patients with jejunal pouch reconstruction after total gastrectomy: A randomized prospective study
20. Patterns of failure following curative resection of gastric carcinoma
21. British Stomach Cancer Group: Resection line disease in stomach cancer
22. Clinicopathologic characteristics of gastric cancer patients with cancer infiltration at surgical margin at gastrectomy
23. Gastrectomy for advanced gastric carcinoma with serosal involvement
24. Positive proximal resection margins after resection for carcinoma of the oesophagus and stomach: Effect on survival and symptom recurrence
25. Prognostic value of resection-line involvement in patients undergoing curative resections for gastric cancer
26. Histologically positive esophageal margin in the surgical treatment of gastric cancer
27. Effect of microscopic resection line disease on gastric cancer survival
28. Total versus subtotal gastrectomy for adenocarcinoma of the gastric antrum: A French prospective controlled study
29. Subtotal versus total gastrectomy for gastric cancer: Five-year survival rates in a multicenter randomized Italian trial: Italian Gastrointestinal Tumor Group
30. A prospective randomized trial comparing R1 subtotal gastrectomy with R3 total gastrectomy for antral cancer
31. Lymph node dissection for gastric cancer
32. Extended operations in cancer - Gastric cancer
33. Lymph node metastases of gastric cancer: General pattern in 1,931 patients
34. Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A Southwest Oncology Group study
35. End results of gastrectomy for gastric cancer: Effect of extensive lymph node dissection
36. Evaluation of extended lymph node dissection for gastric cancer
37. Evaluation of extensive lymph node dissection for carcinoma of the stomach
38. Should systematic lymph node dissection be recommended for gastric cancer?
39. Randomized comparison of R 1 and R2 gastrectomy for gastric carcinoma
40. Gastric carcinoma: Does lymph node dissection alter survival?
41. Prognostic factors in gastric carcinoma: Results of the German Gastric Carcinoma Study 1992
42. Morbidity of radical lymphadenectomy in the curative resection of gastric carcinoma
43. Preservation of the spleen improves survival after radical surgery for gastric cancer
44. Immunohistochemically detected micrometastases of the lymph nodes in patients with gastric carcinoma
45. Evaluation of the necessity for gastrectomy with lymph node dissection for patients with submucosal invasive gastric cancer
46. Early gastric cancer: 46 Cases treated in one surgical department
47. Recurrence of early gastric cancer: Follow-up of 1,475 patients and review of the Japanese literature
48. Analysis of 154 actual five-year survivors of gastric cancer
49. Regional lymph node metastasis of early gastric cancer
50. Strategy for lymphadenectomy of gastric cancer
51. Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: A prospective randomized trial of the Italian Oncology Group for Clinical Research
52. Risk factors for lymph node metastasis from intramucosal gastric carcinoma
53. News of TNM and its use for classification of gastric cancer